Creutzfeldt-Jakob Disease: Prion Disease Mechanisms

Creutzfeldt-Jakob Disease: Prion Disease Mechanisms

> Comprehensive overview of CJD including prion propagation, PRNP mutations, biomarkers, subtypes, and comparison with vCJD

Overview

Creutzfeldt-Jakob Disease (CJD) is the most common human prion disease, characterized by rapid progressive dementia, ataxia, myoclonus, and characteristic neuropathological findings including spongiform change, neuronal loss, and astrocytic gliosis. The disease results from the conformational conversion of the normal cellular prion protein (PrP^C) into the pathogenic isoform (PrP^Sc)[@prusiner_prion].

CJD represents a unique category of neurodegenerative disease — it is the only condition known to be caused by a protein-only infectious agent (prion), which can be genetic, sporadic, or acquired. This mechanistic page covers prion propagation, genetic determinants, diagnostic biomarkers, and disease subtypes.

The Prion Protein

Normal Cellular Prion (PrP^C)

The prion protein is encoded by the PRNP gene on chromosome 20p13[@rutherford_prnp]:

| Property | Value |
|----------|-------|
| Gene | PRNP |
| Protein size | 253 amino acids |
| Molecular weight | ~33-35 kDa |
| Structure | Alpha-helix rich (N-terminal flexible, C-terminal globular) |
| Expression | Highest in CNS, widespread peripheral expression |
| Function | Proposed: copper binding, synaptic function, neuroprotection |

Pathogenic Isoform (PrP^Sc)

Creutzfeldt-Jakob Disease: Prion Disease Mechanisms

> Comprehensive overview of CJD including prion propagation, PRNP mutations, biomarkers, subtypes, and comparison with vCJD

Overview

Creutzfeldt-Jakob Disease (CJD) is the most common human prion disease, characterized by rapid progressive dementia, ataxia, myoclonus, and characteristic neuropathological findings including spongiform change, neuronal loss, and astrocytic gliosis. The disease results from the conformational conversion of the normal cellular prion protein (PrP^C) into the pathogenic isoform (PrP^Sc)[@prusiner_prion].

CJD represents a unique category of neurodegenerative disease — it is the only condition known to be caused by a protein-only infectious agent (prion), which can be genetic, sporadic, or acquired. This mechanistic page covers prion propagation, genetic determinants, diagnostic biomarkers, and disease subtypes.

The Prion Protein

Normal Cellular Prion (PrP^C)

The prion protein is encoded by the PRNP gene on chromosome 20p13[@rutherford_prnp]:

| Property | Value |
|----------|-------|
| Gene | PRNP |
| Protein size | 253 amino acids |
| Molecular weight | ~33-35 kDa |
| Structure | Alpha-helix rich (N-terminal flexible, C-terminal globular) |
| Expression | Highest in CNS, widespread peripheral expression |
| Function | Proposed: copper binding, synaptic function, neuroprotection |

Pathogenic Isoform (PrP^Sc)

The scrapie isoform (PrP^Sc) differs from PrP^C in its:

• Conformational change: From alpha-helix rich to beta-sheet dominant (40% beta-sheet)
• Aggregation: Forms oligomers and fibrils
• Resistance: Protease-resistant core (PrP^Res)
• Infectivity: Template for conversion of normal PrP^C

Prion Conversion Mechanism

Conversion Pathway

The prion conversion mechanism involves[@caughey_prion]:

PRNP Gene Mutations

Disease-Causing Mutations

Over 50 pathogenic mutations in PRNP cause inherited prion diseases[@hsiao_prnp]:

| Mutation | Disease | Phenotype |
|----------|---------|-----------|
| P102L | GSS | Gerstmann-Sträussler-Scheinker syndrome |
| A117V | GSS | Ataxia, dementia |
| D178N | fCJD | Fatal familial insomnia + CJD |
| E200K | fCJD | Most common genetic CJD |
| V180I | fCJD | Japanese founder mutation |
| M232R | fCJD | Incomplete penetrance |
| Octapeptide insert | GSS | Variable phenotype |

Polymorphisms and Risk

Common polymorphisms modify CJD risk[@wadt_prnp]:

| Polymorphism | Effect |
|--------------|--------|
| M129V | Methionine (129M) increases sCJD risk |
| E219K | Glutamate (129E) reduces CJD risk |
| P101L | Associates with GSS |

The 129M/V polymorphism is particularly important:

• 129M homozygous: Higher sCJD risk
• 129V: Associated with vCJD susceptibility

CJD Subtypes

1. Sporadic CJD (sCJD)

Epidemiology[@mecrfi_cjd]:

• Incidence: 1-2 per million per year
• Median age at onset: 65 years
• No known cause or risk factors

| Type | 129 Genotype | Clinicopathological Features |
|------|--------------|------------------------------|
| MM1 | MM | Most common (70%), classic presentation |
| VV2 | VV | Ataxic variant, cortical involvement |
| MV2 | MV | Intermediate, kuru-type plaques |
| MM2 | MM | cortical: slowly progressive; striatal: ataxia |

2. Genetic CJD (gCJD)

PRNP mutations cause ~10-15% of CJD cases[@zanussi_cjd]:

• Autosomal dominant inheritance
• Variable age at onset (40-80 years)
• Variable disease duration (months to years)
• Similar clinical phenotype to sCJD but often slower progression

3. Iatrogenic CJD (iCJD)

Transmission routes:

• Dura mater graft transplantation (historically)
• Cornea transplantation
• Human growth hormone/FSH replacement
• Blood transfusion (rare, vCJD)

4. Variant CJD (vCJD)

Characteristics[@watts_vcjd]:

• Caused by BSE (mad cow disease) exposure
• Younger age at onset (30 years)
• Longer disease duration (12-14 months)
• Psychiatric/behavioral onset
• Prominent kuru-type amyloid plaques

• Causative agent: Bovine spongiform encephalopathy
• Dietary exposure to infected beef (1980s-1990s)
• Species barrier crossing from bovine to human
• Blood transfusion transmission confirmed[@brown_vcjd]

Clinical Features

Core Symptoms

• Rapidly progressive dementia: Decline over weeks to months
• Myoclonus: Classic involuntary jerks
• Ataxia: Cerebellar dysfunction
• Cortical blindness (Heidenhain sign)
• Pyramidal signs: Weakness, spasticity
• Extrapyramidal signs: Rigidity, dystonia

Diagnostic Criteria

MRI findings:

• Cortical ribboning (DWI/FLAIR)
• Basal ganglia hyperintensities
• "Cotton-wool" appearances

• Periodic sharp wave complexes (PSWC)
• 1-2 Hz generalized patterns
• Later in disease course

Biomarkers

14-3-3 Proteins

The 14-3-3 protein detection in CSF is a key diagnostic marker[@singh_cjd]:

| Feature | Value |
|---------|-------|
| Sensitivity | 94% for sCJD |
| Specificity | 75-85% (vs. other dementias) |
| Confounders | Recent seizures, infarction |

Mechanism: 14-3-3 proteins are released from damaged neurons

RT-QuIC

Real-Time Quaking-Induced Conversion is highly sensitive[@bongianni_cjd]:

| Feature | Value |
|---------|-------|
| Sensitivity | 88-95% |
| Specificity | 98-100% |
| Sample | CSF, nasal brushings |
| Time | 2-5 days |

Principle: Recombinant PrP substrate converts in presence of PrP^Sc seeds

Other Biomarkers

| Biomarker | Description |
|-----------|-------------|
| Tau protein | Elevated in CSF, correlates with progression |
| S100B | Astrocyte damage marker |
| Neuronal-specific enolase | Neuronal loss marker |
| PrP^Sc in blood | Research stage, RT-QuIC on blood |

Neuropathology

Spongiform Change

• Vacuolation of neuropil
• Status spongiosus
• Most prominent in cerebral cortex, basal ganglia, cerebellum

Other Findings

• Neuronal loss: Severe, cortical and subcortical
• Astrocytic gliosis: Prominent
• PrP deposition: Varied patterns (perivacuolar, synaptic, plaque)
• Kuru-type plaques: In MV2 and vCJD

Comparison with Other Prion Diseases

| Disease | Agent | Transmission | Key Features |
|---------|-------|--------------|--------------|
| sCJD | PrP^Sc | Sporadic | Rapid dementia, myoclonus |
| fCJD | PrP^Sc | Genetic (PRNP) | Family history |
| iCJD | PrP^Sc | Iatrogenic | Exposure history |
| vCJD | PrP^Sc | Dietary (BSE) | Young, psychiatric |
| GSS | PrP^Sc | Genetic | Ataxia, amyloid plaques |
| FFI | PrP^Sc | Genetic | Insomnia, autonomic failure |

Comparison with Similar Diseases

vCJD vs. sCJD

| Feature | vCJD | sCJD |
|---------|------|------|
| Age at onset | 20-40 years | 60-70 years |
| Disease duration | 12-14 months | 4-6 months |
| Onset type | Psychiatric/behavioral | Cognitive/motor |
| MRI | Prominent pulvinar sign | Cortical/basal ganglia |
| PrP plaques | Floral kuru-type | Rare |

Feline Spongiform Encephalopathy (FSE)

FSE in cats is caused by BSE infection[@gardside_fse]:

• Similar neuropathology to vCJD
• Dietary exposure to BSE-contaminated food
• First described in 1990s

Therapeutic Approaches

Current Status

No disease-modifying therapy exists. Supportive care is the mainstay:

• Symptomatic treatment of myoclonus (clonazepam, valproate)
• Management of dysphagia
• Nutritional support
• Palliative care

Clinical Trials

| Approach | Status | Notes |
|----------|--------|-------|
| Pentosan polysulfate | Negative | No survival benefit |
| Quinacrine | Negative | No clinical benefit |
| Flupirtine | Negative | Trial stopped |
| Antibiotics (doxycycline) | Mixed | Some positive signals |

Experimental Approaches

| Strategy | Target | Stage |
|----------|--------|-------|
| Anti-PrP antibodies | PrP^Sc | Preclinical |
| PrP^Sc aggregation inhibitors | PrP conversion | Preclinical |
| Gene silencing | PRNP expression | Research |
| Stem cell approaches | Neuronal replacement | Early research |

Summary

CJD represents the prototype of prion diseases — protein-misfolding disorders that can be sporadic, genetic, or infectious. The understanding of prion biology, developed over decades of research, has provided fundamental insights into other neurodegenerative diseases characterized by protein aggregation.

Key Takeaways:

• PrP^Sc conversion is the central pathogenic event
• PRNP mutations cause genetic CJD; codon 129 modifies phenotype
• RT-QuIC and 14-3-3 are key diagnostic biomarkers
• vCJD is a distinct entity linked to BSE exposure
• No effective disease-modifying therapy exists to date

Related Mechanisms

• [Alpha-Synuclein Prion-Like Propagation](/mechanisms/alpha-synuclein-parkinson-propagation)
• [TDP-43 Proteinopathy in ALS/FTD](/mechanisms/tdp-43-fus-rna-proteinopathy-comparison)
• [Tau Aggregation in AD/FTD](/mechanisms/ad-ftd-tau-tdp-overlap-comparison)